Xeris Pharmaceuticals: Nasdaq Inducement Grants Approved

Xeris Biopharma Incentivizes New Hires with $383K Stock Grant

A strategic equity award aims to bolster Xeris biopharma’s growing team as the company advances its pipeline and commercial products.

Xeris biopharma Holdings, Inc. (Nasdaq: XERS) announced on Thursday, October 1, 2025, that its Compensation Committee approved the granting of restricted stock units (RSUs) totaling 382,975 shares of common stock to 40 new employees. This move,executed under the company’s Inducement Equity Plan,is designed to attract and retain top talent.

Did you know? – restricted stock units are a common form of compensation in the biopharmaceutical industry, offering employees a stake in the company’s future success. Thay become actual shares over time.

Attracting Talent Through Equity

The Inducement Equity Plan is specifically designed for individuals new to Xeris or its subsidiaries. According to a company release, the plan provides a material incentive for these individuals to join the organization, adhering to Rule 5635(c)(4) of the NASDAQ Listing Rules. This practice is common in the competitive biopharmaceutical industry, where attracting skilled personnel is crucial for innovation and growth.

The RSUs will vest over three years, with equal installments awarded annually, contingent upon continued employment. This vesting schedule encourages long-term commitment from the new hires. All equity awards are governed by the terms outlined in Xeris’ Inducement Equity plan and related award agreements.

Pro tip: – Vesting schedules are designed to align employee interests with company performance. Employees must remain with the company to fully realize the value of the stock units.

Xeris Biopharma: A Growing Portfolio

Xeris biopharma is a rapidly expanding company focused on developing and commercializing innovative therapies.Currently, Xeris boasts three commercially available products:

• Recorlev®: Used in the treatment of endogenous Cushing’s syndrome.
• Gvoke®: A ready-to-use liquid glucagon for treating severe hypoglycemia. It also functions as a gastrointestinal motility inhibitor for diagnostic purposes.
• Keveyis®: A proven therapy for primary periodic paralysis.

Beyond its existing portfolio, Xeris is actively developing a robust pipeline. Leading the charge is XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism. The company is also pursuing early-stage programs utilizing its proprietary technology platforms, XeriSol® and XeriJect®, in collaborat

Reader question: – How might this investment in personnel impact Xeris biopharma’s ability to bring new therapies to market? what challenges might they face?